Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity.

Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M, Fujita T, Watanabe M.

Hepatology. 2013 Jan;57(1):46-58. doi: 10.1002/hep.26017.

PMID:
22911572
2.

Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression.

Kaukinen P, Sillanpää M, Kotenko S, Lin R, Hiscott J, Melén K, Julkunen I.

Virol J. 2006 Sep 1;3:66.

3.

Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage.

Welsch C, Haselow K, Gouttenoire J, Schneider M, Morikawa K, Martinez Y, Susser S, Sarrazin C, Zeuzem S, Antes I, Moradpour D, Lange CM.

J Hepatol. 2015 Apr;62(4):779-84. doi: 10.1016/j.jhep.2014.11.009. Epub 2014 Nov 21.

PMID:
25463536
4.
5.

Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.

Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD.

Antimicrob Agents Chemother. 2013 Sep;57(9):4417-26. doi: 10.1128/AAC.00399-13. Epub 2013 Jul 8.

6.

Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.

Johnson CL, Owen DM, Gale M Jr.

J Biol Chem. 2007 Apr 6;282(14):10792-803. Epub 2007 Feb 8.

7.

Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity.

Ding Q, Cao X, Lu J, Huang B, Liu YJ, Kato N, Shu HB, Zhong J.

J Hepatol. 2013 Jul;59(1):52-8. doi: 10.1016/j.jhep.2013.03.019. Epub 2013 Mar 28.

PMID:
23542348
8.

Differential, type I interferon-mediated autophagic trafficking of hepatitis C virus proteins in mouse liver.

Desai MM, Gong B, Chan T, Davey RA, Soong L, Kolokoltsov AA, Sun J.

Gastroenterology. 2011 Aug;141(2):674-85, 685.e1-6. doi: 10.1053/j.gastro.2011.04.060. Epub 2011 May 6.

9.

Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0.

Horner SM, Park HS, Gale M Jr.

J Virol. 2012 Mar;86(6):3112-20. doi: 10.1128/JVI.06727-11. Epub 2012 Jan 11.

10.

Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon.

Breiman A, Grandvaux N, Lin R, Ottone C, Akira S, Yoneyama M, Fujita T, Hiscott J, Meurs EF.

J Virol. 2005 Apr;79(7):3969-78.

11.

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J.

Nature. 2005 Oct 20;437(7062):1167-72. Epub 2005 Sep 21.

PMID:
16177806
12.

Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway.

Paz S, Sun Q, Nakhaei P, Romieu-Mourez R, Goubau D, Julkunen I, Lin R, Hiscott J.

Cell Mol Biol (Noisy-le-grand). 2006 May 15;52(1):17-28.

PMID:
16914100
13.

MDA5 plays a critical role in interferon response during hepatitis C virus infection.

Cao X, Ding Q, Lu J, Tao W, Huang B, Zhao Y, Niu J, Liu YJ, Zhong J.

J Hepatol. 2015 Apr;62(4):771-8. doi: 10.1016/j.jhep.2014.11.007. Epub 2014 Nov 21.

PMID:
25463548
14.

Hepatitis C Virus NS4B Can Suppress STING Accumulation To Evade Innate Immune Responses.

Yi G, Wen Y, Shu C, Han Q, Konan KV, Li P, Kao CC.

J Virol. 2015 Oct 14;90(1):254-65. doi: 10.1128/JVI.01720-15. Print 2016 Jan 1. Erratum in: J Virol. 2018 Jan 2;92 (2):.

15.

GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS.

Chen Z, Benureau Y, Rijnbrand R, Yi J, Wang T, Warter L, Lanford RE, Weinman SA, Lemon SM, Martin A, Li K.

J Virol. 2007 Jan;81(2):964-76. Epub 2006 Nov 8.

16.

Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.

Liang Y, Ishida H, Lenz O, Lin TI, Nyanguile O, Simmen K, Pyles RB, Bourne N, Yi M, Li K, Lemon SM.

Gastroenterology. 2008 Nov;135(5):1710-1718.e2. doi: 10.1053/j.gastro.2008.07.023. Epub 2008 Jul 22.

PMID:
18725224
17.

Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes.

Wang Y, Ye L, Wang X, Li J, Song L, Ho W.

Innate Immun. 2013;19(2):193-202. doi: 10.1177/1753425912460414. Epub 2012 Oct 11.

18.

Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A protease.

Hiscott J, Lacoste J, Lin R.

Biochem Pharmacol. 2006 Nov 30;72(11):1477-84. Epub 2006 Jul 31.

PMID:
16876765
19.

Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.

Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M Jr.

Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2986-91. Epub 2005 Feb 14.

20.

DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-beta-inducing potential.

Oshiumi H, Sakai K, Matsumoto M, Seya T.

Eur J Immunol. 2010 Apr;40(4):940-8. doi: 10.1002/eji.200940203.

Supplemental Content

Support Center